Moderna's Trading Volume Drops 46.94% to $209 Million, Stock Falls to 417th in Daily Rankings

On May 28, 2025, Moderna's trading volume reached $209 million, marking a 46.94% decrease from the previous day. The company's stock price fell by 2.65%, placing it at the 417th position in the daily market rankings.

Moderna has announced that it will explore alternative strategies for the late-stage development and manufacturing of its H5 program, aligning with the company's strategic commitment to pandemic preparedness. This decision comes as Moderna continues to navigate the complexities of its investigational pandemic influenza program.

In a significant development, Moderna reported positive interim data from a Phase 1/2 clinical study evaluating the safety and immunogenicity of its investigational vaccine. This study, involving 300 healthy adults, has shown promising early results, indicating the potential efficacy of Moderna's avian flu vaccine, mRNA-1018.

Moderna has also faced setbacks, including the cancellation of a $766 million contract by the Trump administration to develop a vaccine against potential pandemic influenza viruses. Additionally, the company recently withdrew its biological license application for a combination COVID-19/flu vaccine, citing the need for additional data.

Despite these challenges, Moderna's investigational vaccine, mRNA-1083, has demonstrated noninferiority to other vaccines in a large study, with an acceptable tolerability profile. This suggests that Moderna continues to make progress in its vaccine development efforts, even as it encounters obstacles along the way.